WCN26-390 A PHASE-4, 52-WEEK, SINGLE ARM, POST-MARKETING SURVEILLANCE TO EVALUATE SAFETY OF DESIDUSTAT FOR TREATMENT OF ANEMIA IN SUBJECTS WITH CHRONIC KIDNEY DISEASE